Pembrolizumab

Mohammed Milhem presents preliminary data on the combination of the TLR9 agonist CMP-001 and pembrolizumab in patients with metastatic melanoma resistant to anti-PD-1.

TLR9 agonist CMP-001-pembrolizumab combination shows early efficacy in patients with metastatic melanoma resistant to anti-PD-1.

In the study, the combination of chemotherapy with pembrolizumab performed significantly better in terms of ORR, PFS and OS.

Alexander M. M. Eggermont, MD, PhD, director general of Gustave Roussy Cancer Campus Grand Paris in Villejuif, France, talks about the key findings of the KEYNOTE-054 trial and highlights pembrolizumab's high therapeutic index.

In the KEYNOTE-054/EORTC 1325 MG-trial, patients randomized to pembrolizumab were 43 percent less likely to have recurrence.

The results of the placebo controlled double blind phase III study Keynote 054 will be presented at the AACR annual meeting.

Combinations of immune checkpoint inhibitors and chemotherapy show promising results. Results of the the KEYNOE 189 study will be presented at the AACR.